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Abstract
The effect of the treatment with glycolipid derivatives on the metabolic profile of intact glioma cells and tumor tissues,
investigated using proton high resolution magic angle spinning (1H HR-MAS) nuclear magnetic resonance (NMR)
spectroscopy, is reported here. Two compounds were used, a glycoside and its thioglycoside analogue, both
showing anti-proliferative activity on glioma C6 cell cultures; however, only the thioglycoside exhibited antitumor
activity in vivo. At the drug concentrations showing anti-proliferative activity in cell culture (20 and 40 µM), significant
increases in choline containing metabolites were observed in the 1H NMR spectra of the same intact cells. In vivo
experiments in nude mice bearing tumors derived from implanted C6 glioma cells, showed that reduction of tumor
volume was associated with significant changes in the metabolic profile of the same intact tumor tissues; and were
similar to those observed in cell culture. Specifically, the activity of the compounds is mainly associated with an
increase in choline and phosphocholine, in both the cell cultures and tumoral tissues. Taurine, a metabolite that has
been considered a biomarker of apoptosis, correlated with the reduction of tumor volume. Thus, the results indicate
that the mode of action of the glycoside involves, at least in part, alteration of phospholipid metabolism, resulting in
cell death.
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Introduction
The strategy of applying analytical chemistry methods to
monitor anti-cancer therapy effects is based on the principle
that the interaction of drugs with cells and tissues affects the
network of metabolic pathways occurring within cells. This
interaction could change the concentration of metabolites
associated with the altered pathway and proton high resolution
(1H HR) NMR spectroscopy offers the possibility of acquiring a
snapshot of the sample chemistry, providing, in a single
measurement, qualitative and quantitative information of
hundreds of metabolites. The complete spectrum can be used
as a fingerprint of the metabolic status of cells or tissues [1].
Analysis of intact tissue using 1H HR magic angle spinning
(MAS) NMR spectroscopy provides spectra with high resolution
and requires minimal sample preparation, allowing the
observation of tissue metabolites in their native state [2,3].
These advantages, together with the potential of 1H HR-MAS
NMR spectroscopy to identify biomarkers for cancer diagnosis,
prognosis and evaluation of therapies, have lead to an
increasing use of this methodology during the last decade [4].
Complementary with that, in vitro NMR spectroscopy studies of
cancer cells, intact and after drug treatment, allow the
systematic determination of a large number of metabolites
which may provide valuable information on cellular processes.
The comparison of the results of NMR spectroscopy studies of
cell cultures and tumor biopsies thus facilitates the correlative
interpretation of in vitro and in vivo drug activity, and allows
evaluation of the suitability and limitations of each model
system.
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We have previously described the synthesis of glycolipids
with antitumor activity [5]. Among the variety of glycosides with
different hydrocarbon chains in the aglycone moiety, the most
active glycoside was compound 1, which contains an oleyl
chain (Figure 1). The favorable effect of an oleyl chain on the
antitumor activity was also observed in a family of alkylated
iminosugars [6]. Further studies [7,8] designed to understand
the mechanism behind the activity of 1 on lung carcinoma A549
and glioma C6 cells showed that, at concentrations above 30
µM, glycoside 1 drastically altered the cell lipid profile, with a
significant increase in sphingolipid and glycosphingolipid levels,
that eventually resulted in cell death [8]. Despite its promising
activity against cancer cells in culture, glycoside 1 was inactive
when tested in mice bearing an implanted C6 glioma. This lack
of activity was attributed to the hydrolysis of 1 by
hexosaminidase enzymes generated by activated
macrophages [9]. This hypothesis was confirmed by using the
enzyme resistant thioglycoside 2 (Figure 1), which reduced
significantly the mice tumor volume compared to controls [9].
The antitumor activity of thioglycoside 2, together with
previous results showing alterations on glycosphingolipid levels
in tumor cells after compound 2 treatment, indicate the interest
of obtaining more information about its mode of action.
Accordingly, we hypothesized that drug induced alteration of
lipid content should be reflected in observable changes in
related metabolic pathways. The information on quantitative
response markers could be of great value for the design and
evaluation of new compounds with improved therapeutic
properties. With this objective, we have studied changes in low
molecular weight metabolites after treatment of C6 glioma cells
with 1 and 2, as well as the corresponding mice tumor tissues
derived from implanting these cells, using 1H HR-MAS NMR.
Therefore, the aim of this study was to determine and
compare the metabolic profiles of glycoside-treated and
untreated glioma cells and tissues, as reflected in the NMR
spectra, to gain information on the metabolic impact of the
compounds and to provide a better interpretation for their in
vitro anti-proliferative and in vivo antitumoral activity.
Figure 1.  Chemical structures of glycoside 1 and




Mice were maintained in the animal house of the Cajal
Institute (Madrid, Spain) with ad libitum food and water in a 12-
hours light/dark cycle. Animals were handled complying with
the European Union guidelines for care and handling of
experimental animals (86/609/EEC) and the protocols
approved by the Cajal Institute animal welfare committee.
Chemicals
Compounds 1 and 2 were prepared following procedures
previously described [7,9].
Cell cultures
Rat glioma cells (C6 line, obtained from European Collection
of Cell Cultures, Salisbury, UK) were maintained in DMEM
medium (Sigma-Aldrich, St Louis, MO), supplemented with
fetal bovine serum (FBS, 10%; Gibco, Paisley, UK), penicillin
(50 IU/mL) and streptomycin (50 mg/mL), at 37 °C in a 5% CO2
humidified atmosphere. Exponentially growing C6 cells were
seeded on six-well plates (Beckton Dickinson, Le Pont de
Claix, France), in complete DMEM medium, at a density of 6 x
105 cells/well. The cells were allowed to attach with 5% of CO2
at 37 °C overnight, and then the medium was replaced with 2
mL of fresh medium. For treatments, stock solutions of
compounds 1-2 (100 mM) in EtOH were dissolved in DMEM
medium containing EGF (10 ng/mL). Cells were treated with 20
µM or 40 µM of compounds (1,2) for 48 h. After the treatment,
cells (4 x 105 - 1.2 x 106 cells/well) were trypsinized, centrifuged
at 100 x g for 5 minutes and resuspended in phosphate buffer
solution (PBS) at 4 °C for analysis. Each experiment was
performed in triplicate, and vehicle-treated cells were used as
controls.
C6 glioma tumor samples
The activity of compounds 1 and 2 on tumor growth was
evaluated as previously described [9] using an orthotopic
model in female nude mice (Foxn1nu/nu, 6-8 weeks old, Harlan
Iberica, Barcelona, Spain). Mice were maintained in the animal
house of the Cajal Institute with ad libitum food and water in a
12-hours light/dark cycle. Animals were handled complying with
the European Union guidelines for care and handling of
experimental animals (86/609/EEC) and the protocols
approved by the Cajal Institute animal welfare committee. Mice
were injected into a flank, subcutaneously, a suspension of 2 x
106 cells of rat glioma C6, grown as indicated in the previous
section. Tumor volume was calculated according to the
following formula: V (cm3) = (L x W2 x π)/6, where L is the
length, W is the width of the tumor, respectively. When tumors
reached 250 mm3, the animals were treated with a daily
intratumoral injection of the compounds, for 14 days. Stock
solutions of the compounds (100 mM) in DMSO were dissolved
in PBS containing fatty acid-free BSA (5 mg/mL) for the
treatments. Control animals received injections with only the
vehicle solution (PBS buffer with BSA and DMSO). Four
different groups of mice were studied (control, treated with
Effect of Drug-Treatment on Cells Using HR-MAS NMR
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compound 1 at 10 mg/Kg/day and treated with compound 2 at
two doses, 1 and 10 mg/Kg/day). For each group six tumor
biopsies corresponding to 6 different animals were obtained
(N=6). The animals were sacrificed after 14-days treatments,
and the tumors were immediately resected in ice. The tumors
were cut in two pieces with a sterile surgical blade under a
SMA4 dissecting microscope (Askania). For each tumor, two
types of samples were obtained and analyzed separately: one
from the core of the tumor (representing approximately
5%-10% of total tumor mass) and another from the periphery.
The tumor samples were washed once with deuterated
phosphate buffered solution, frozen in liquid nitrogen and
stored at -80 °C until use.
1H HR-MAS NMR spectroscopy of cell cultures and ex
vivo tumor tissues
1H HR-MAS NMR measurements were performed on a
Bruker spectrometer operating at 16.4 T (proton Larmor
frequency of 700.13 MHz) using a Bruker HR-MAS triple
resonance probe. The spectra were acquired at 4 °C to
minimize the effect of temperature on tissue stability during the
acquisition time and to minimize glycerophosphocholine (GPC)
and phosphocholine (PC) conversion to choline (Cho) and
reduce variations in some amino acids [10]. Sample spinning at
the magic angle was applied at a speed of 6 kHz. The
acquisition sequence and parameters were selected to reduce
the signals of large and low mobility molecules, essentially T2-
filtered (CPMG) 1D experiments were recorded with relaxation
times of 30 and 300 ms (and echo times of 1.5 and 3 ms) for
cells and tissue samples, respectively. Low power
presaturation during the interscan delay of 3 s was applied for
water suppression. Typically, 64 scans were accumulated
using a spectral width of 20 ppm with acquisition times of 2 s
(cells) or 1.6 s (tissues), which resulted in 6 min of acquisition
time per spectrum. The spectra were processed using
MestReNova version 7.0 software (Mestrelab Research,
Santiago de Compostela, Spain). All free induction decays
were processed with exponential multiplication (0.5 Hz line-
broadening) before Fourier transformation, followed by
baseline correction. The chemical shifts were referenced as
follows: a small amount (5 µL) of 10 mM DSS in D2O was
added to one sample of intact cells and to one sample of
tissue, and referenced to DSS = 0 ppm; then all spectra were
processed identically and aligned (using the creatine (Cre)
methyl resonance at 3.026 ppm) with respect to the sample
with added DSS. Out of the various methods to estimate or
measure the intensity of NMR signals [4], we compared peak
intensity ratios using the methyl signal of creatine as internal
reference. Creatine is commonly used as an internal
concentration reference for in vivo 1H NMR, because its
concentration correlates with the number of metabolically
active cells and is used as a measure of viable cell number
[11].
Cultured cells were resuspended, washed three times with
deuterated phosphate buffered solution and centrifuged to form
pellets. Typically, for each sample approximately 60 μL of living
cell pellets were placed into a 4 mm Ø zirconia rotor. Tumor
tissue samples for NMR analysis were thawed in ice, cut in a
few small pieces that were placed and compacted into a 4 mm
Ø zirconia rotor. For both cell and tissue samples a small
amount (5 µL) of D2O-phosphate buffer was added for field-
frequency lock.
Statistical analysis
Statistically significant differences [12-14] were evaluated as
follows: the normal distribution of values was assessed with the
Kolmogorov-Smirnov or Shapiro-Wilk tests and the variance
homogeneity with the Levene´s test. Values with a normal
distribution and homogeneous variance were compared with
unpaired two-tailed Student´s t test or, if more than two
comparisons were carried out, with the ANOVA test. For values
with normal distribution but non-homogeneous variance, the
ANOVA test was carried out not assuming equal variances.
Values with non-normal distribution were evaluated with the
non-parametric Mann-Whitney´s U test or, if more than two
comparisons were carried out, with the Kruskal-Wallis test.
Significance level was set to 0.05, and all analyses were
carried out with SPSS version 19.0 (SPSS Inc., Chicago, IL,
USA). The NMR spectra used to quantify metabolite
differences, and those presented to illustrate them, are the
most representative of three or six independent experiments for
cell culture and tumor tissues, respectively. All data are
expressed as average value ± standard deviation (SD).
Results and Discussion
NMR analysis of C6 cell cultures
The C6 glioma cells were cultured in the presence of two
different concentrations (20 and 40 µM) of glycoside 1 or
thioglycoside 2 for 48 h. A representative 1H NMR spectrum of
control C6 glioma cells after 48 h of incubation is shown in
Figure 2. Spectra in the range between 0.5 to 4.5 ppm are
shown, and the most important variations upon treatment were
observed in the region between 3.00 to 3.45 ppm. Low field
signals were too weak to allow reliable quantification and were
excluded from analysis.
The assignment of relevant, intense and resolved signals
was based on the chemical shifts and known multiplicities
reported for metabolites of cultured glioma cell lines [11,15],
and is illustrated and indicated in a representative spectrum
(Figure 2A). Thus, the quartet at 4.12 ppm corresponds to the
proton in alpha to the carbonyl group of lactate (Lac). This
signal, which was resolved properly, was used to evaluate
changes in this metabolite. Lactate presents another 1H NMR
signal corresponding to its methyl group that appears as a
doublet at 1.3 ppm, overlapping with the resonances of lipid
methylene groups. The three peaks present in the 3.23 ppm
region were assigned to the total choline (tCho) trimethyl
resonance, –N(CH3)3, and consists of at least three main
choline subspecies which were differentiated in the HR spectra:
choline, phosphocholine and glycerophophocholine at 3.206,
3.223 and 3.231 ppm respectively (Figure 2).
Phosphatidylcholine (PdtCho) is a constituent of cell
membranes, and this metabolite can be detected by NMR in
the region of tCho at 3.220 ppm and distinguished from other
choline-containing metabolites. However, the PdtCho
Effect of Drug-Treatment on Cells Using HR-MAS NMR
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Figure 2.  Representative 1H HR-MAS NMR spectra of C6 cells.  (A) Control C6 cells, with an insert corresponding to the total
choline (tCho) region shown on the top (B) tCho region of the spectrum of C6 cells treated with thioglycoside 2 at 20 and 40 µM (C)
tCho region of the spectrum of C6 cells treated with glycoside 1 at 20 and 40 µM.
doi: 10.1371/journal.pone.0078391.g002
Effect of Drug-Treatment on Cells Using HR-MAS NMR
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resonance is attenuated to a greater extent than low molecular
weight metabolites when using a T2-filter, as we did in this
study. This sequence also selectively attenuates resonances
from macromolecules [16,17]. A narrow peak at 3.02 ppm was
assigned to the creatine methyl and employed as internal
reference. Signals between 2.34 and 2.04 ppm were assigned
to glutamate (Glu) and glutamine (Gln) beta and gamma
methylene groups. The singlet at 1.91 ppm was assigned to
free acetate (Ac), since the acetate signal corresponding to
acetylated species, like N-acetyl glucosamine, appears at 2
ppm [18]. A doublet at 1.48 ppm is assigned to alanine (Ala)
and signals at 0.90 ppm correspond to methyl groups of fatty
acyl chains of lipids (Lip).
While cell-treatment with compounds 1 and 2 produced no
significant differences in the levels of aminoacids Glu, Gln, Ala
and valine (Val) at any concentration (neither 20 µM nor 40
µM), the levels of other cell metabolites were affected by the
treatment, as follows.
Cells treated with the lowest concentration of 2 (20 µM)
displayed only slight changes in metabolic profile when
compared to control cells. In contrast, the most significant
metabolic change, a two-fold increase in tCho levels compared
to creatine, was detected after cell treatment with 40 µM of
either glycoside 1 or thioglycoside 2. Specifically, the levels of
Cho and PC increased 2 and 3 times, respectively, and there
was a significant rise in the ratio PC/GPC (1.45±0.61 versus
0.70±0.33), due to a greater increase of PC in treated cells
(Figure 2, Table 1). Moreover, most of these effects observed
in cells treated with glycoside 1 or thioglycoside 2 were
concentration-dependent, increasing from 20 to 40 µM level.
Previous studies on lipophilic cell extracts had shown that
compound 1, at concentrations above 30 µM, causes increases
in ceramide levels and activates endoplasmic reticulum stress
response pathways [8], which can induce apoptotic response in
cells [17,19]. The reason for this increase of ceramide levels
still remains unknown; however, the results obtained in this
work are consistent with a buildup of free ceramide due to the
hydrolysis of sphingomyelin (SM) catalized by
sphingomyelinases [20], contributing to the high levels of PC
detected here by NMR spectroscopy upon treatment with
compounds 1 and 2. SM is a major constituent of plasma
membranes, and it has been reported that inhibitors of
sphingomyelinases block apoptotic cell death in culture [21].
Accordingly, the mode of action of the glycosides used here
could involve the direct or indirect functional activation of these
sphingomyelinases, resulting in the accumulation of ceramide,
which leads to cell apoptosis [22,23]. On the other hand,
apoptosis induced by various drugs has been associated with
changes in PC in hamster and human cell lines [24], therefore
the choline metabolite perturbation detected here could be the
final consequences of the treatment (stress response and
apoptosis) and not necessarily part of the compounds action
pathway.
Abnormal choline metabolism has been associated with
oncogenesis and tumor progression. The enzymes involved in
choline metabolism have been extensively studied as attractive
targets for drug development [25,26]. After malignant
transformation, the modulation of enzymes that control
anabolic and catabolic pathways causes increased levels of
choline-containing precursors and breakdown products of
membrane phospholipids. The increased levels in tCho present
in most cancers are associated with proliferation; besides, as
emphasized in a recent review [27], there are complex
reciprocal interactions between oncogenic signaling and
choline metabolism. However, there are considerable
differences in the relative contribution of individual choline-
containing metabolites between cancer subtypes and, also,
after drug treatments. The low PC and high GPC levels
observed in non-malignant cells change to high PC and low
GPC levels after malignant transformation [28]. Recent studies
of highly malignant human breast cancer cell lines and in
human tumors displaying malignant choline metabolite profiles
(high PC and low GPC levels) have shown increased
expression of glycerophosphocholine phosphodiesterase,
which catalyzes the degradation of GPC to free choline and
glycerol-3-phosphate. The authors suggest that this enzyme is
most likely involved in membrane PtdCho metabolism [29]. Our
results indicate that C6 glioma cell treatment with glycosides
produces an increase in Cho and PC but not a decrease in
GPC, which suggests that other choline-related metabolic
pathways are also involved, at least in these cells.
Sphingomyelinases, which have emerged as important players
in modulating oxidative stress-mediated neural cell death in
brain tissue [30], are preferentially located in plasma
membranes and lysosomes/endosomes [20] and catalyze the
cleavage of the phosphodiester bond in SM to form ceramide
and PC. Thus, these enzymes could be involved in cancer
pathogenesis and may potentially contribute to the elevated PC
levels that constitute the cholinic phenotype (Figure 3).
Inhibition of choline kinase-α has been reported to increase
ceramide levels and, therefore, sphingomyelinases may have a
role in the action of choline kinase-α inhibitors as antitumoral
drugs [31].
Therefore, we suggest that treatment with compounds 1 and
2 could result in activation of sphingomyelinases (Figure 3),
that may contribute to the high levels of PC detected here with
proton NMR spectroscopy and to the increase in ceramide
levels observed previously [8]. This activation of
sphingomyelinases could, directly or indirectly, lead to
Table 1. Quantification of intracellular metabolites in C6
glioma cells upon glycoside treatment(a).
Metabolite Signal Control 2 (20 µM) 2 (40 µM) 1 (20 µM) 1 (40 µM)
GPC 3.23, s 1.52±0.30 1.77±0.19 1.90±0.43 1.73±0.62 2.42±0.28
PC 3.22, s 1.07±0.21 1.66±0.31 2.76±0.77 2.41±0.72 2.82±0.15
Cho 3.20, s 0.66±0.32 0.76±0.12 1.21±0.43 1.11±0.31 1.87±0.55
tCho 3.2, m 3.25±0.83 4.19±0.62 5.87±1.63 5.25±1.65 7.11±0.98
PC/GPC  0.70±0.33 0.94±0.33 1.45±0.61 1.39±0.80 1.17±0.19
Lac 4.11, q 0.32±0.09 0.19±0.10 0.26±0.10 0.23±0.15 0.32±0.07
Ac 1.91, s 0.16±0.05 0.21±0.10 0.29±0.09 0.31±0.04 0.58±0.13
a. Relative intensity to creatine (I/Icreatine). Results represent the mean ± SD of
three experiments.
doi: 10.1371/journal.pone.0078391.t001
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activation of apoptosis mediated by endoplasmic reticulum
stress.
There are other conditions where increased levels of PC in
cells have been detected. For instance, a recent study showed
that the concentration of PC in glioma cells increased after
nutrient deprivation [32]. Alterations in the PC/GPC ratio
indicate changes in choline homeostasis [33] and PtdCho
metabolism [34,35]. An increase in tCho, associated with
increased GPC levels, was identified in growth arrested human
prostate carcinoma [36], suggesting that the relative alteration
in choline containing metabolites and, in particular, PC/GPC
may be a reliable indicator of cell stress. Changes in individual
choline metabolites after different types of treatment have been
reported; however, neither a general pattern of responses of
the individual choline containing metabolites, nor of tCho is
documented [4]. We have observed that the treatment of C6
glioma cells with compounds 1 and 2 produces an increase in
tCho, mainly due to an increase in levels of Cho and PC, but
not GPC. Thus, cancer cell treatments with anti-proliferative
compounds 1 and 2, which result in an increase in tCho, could
be effective due to the activation of sphingomyelinases that
induce endoplasmic reticulum stress responses causing
apoptosis, but could have the opposite effect of other
chemotherapies which reduce tCho levels.
Other metabolite that significantly increases upon treatment
with the two compounds, and does so in a dose-response
manner, is acetate. Acetate is a short chain fatty acid, an
essential building block for synthesis of many metabolites. It
has been detected by NMR in normal rat brain, human
resected tissues and cell cultures [11]. The increased levels of
acetate could be produced under insufficient oxygen supply by
the mediation of cytosolic acetyl acetyl-CoA synthetase [37].
NMR analysis of intact tumor tissues.  The activity of
compounds 1 and 2 on tumor growth was evaluated using an
orthotopic model in female nude mice. Although glycoside 1
presented a higher anti-proliferative activity on C6 cells in
culture than compound 2, only tumors treated with the highest
dose of thioglycoside 2 were significantly reduced in size
compared to controls [9]. After the in vivo experiment, two
different tumor biopsy samples were dissected and analyzed:
samples from the core and samples from the periphery of the
tumor. As expected from its contact with the implantation site,
tissue samples from the tumor periphery presented greater
amounts of lipids and increased heterogeneity (not shown);
therefore, we focused on the analysis of core tumor samples. A
representative 1H HR-MAS NMR spectrum of control C6 tumor
core tissue is shown in Figure 4.
Several new and relevant resonances appear in the tumor
spectra, which are well resolved and can be assigned due to
the high resolution of the spectra, such as the singlet a 3.55
ppm, assigned to the two methylene protons of glycine (Gly),
an amino acid distributed throughout the brain and nervous
system, and characteristic of glial tumors [38]. The two triplets
at 3.45 and 3.25 ppm correspond to taurine (Tau) (2-
aminoethanesulfonic acid). The singlet centered at 3.33 ppm
was ascribed to scyllo-inositol (S-Inositol) [39], which is the
second most abundant isomer of inositol found in mammals,
and can be detected in human brain using magnetic resonance
spectroscopy [40] and in human prostate using magnetic
resonance spectroscopic imaging [41]. However, this
resonance has been detected only in a few samples (three of
six samples) of the tumors treated with the highest dose of
thioglycoside 2 (1.5±1.7 intensity of S-Inositol relative to
creatine, Table 2). The concentration of S-Inositol seems to be
Figure 3.  Schematic representation of the possible mechanism for deregulated choline cancer metabolism with drug
treatment.  Black arrows in Cho and PC indicate a rise in the levels of these metabolites detected in this study.
doi: 10.1371/journal.pone.0078391.g003
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Figure 4.  Representative 1H HR-MAS NMR spectra of C6 tumor core tissue.  (A) Tumor of control mice (B) Tumor of 2-treated
mice (1 mg/Kg) (C) Tumor of 2-treated mice (10 mg/Kg). The complete aliphatic region is shown on the left panels, and expansion
of the taurine and creatine regions on the right, asterisks: ethanol contamination.
doi: 10.1371/journal.pone.0078391.g004
Effect of Drug-Treatment on Cells Using HR-MAS NMR
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tightly coupled to the myoinositol (mI) concentration at a ratio of
12 mI: 1 S-Inositol [39], so that the elevated S-Inositol might
provide indirect evidence of elevated mI. By contrast, our
results showed no variations in mI content of tumor tissues with
any treatment respect to controls, following its resonance at
3.97 ppm (0.21±0.03 and 0.24±0.04 intensity of mI relative to
creatine, for controls and for treatment with 10 mg/Kg/day of
compound 2, respectively). The prominent S-Inositol peak in
these tumor tissues deserves further study before its clinical
significance can be assessed. Concerning the choline region, a
new peak resolved only in tissue spectra and not in cell spectra
appeared at 3.21 ppm. This peak has been tentatively
assigned to carnitine (Carn), which is a low molecular
metabolite containing (as the 3 choline-containing metabolite
signals) the group –N(CH3)3 in its chemical structure. The most
apparent difference of tissue spectra (Figure 4) when
compared to the corresponding cells in culture (Figure 2) is the
detection of significantly smaller levels of total choline (a
maximum of 2 in tissue, versus 7 in cells, when normalized to
creatine methyl intensities).
Significant variations in the spectra of tumors were detected
only in tumors treated with the highest dose of 2 (10 mg/Kg/
day), whereas treatment with 1, which is susceptible of
enzymatic hydrolysis in vivo, resulted in low, non-significant
and variable changes. The most significant metabolic change
detected in treated tumor tissues with the highest dose of 2
was a significant increase in Cho (2 times) and PC (1.4 times)
levels, similar to the results obtained in cell culture; the ratio
PC/GPC was also higher (1.69±0.68 versus 1.34±0.5) in
treated tumors (Table 2). On the other hand, the tumors treated
with glycoside 1, which had in vitro activity on cells but was
inactive in vivo (as judged by its inability to reduce tumor
volume, probably due, among other factors, to its hydrolysis in
vivo) [9], showed NMR spectra consistently similar to those of
control tissue samples. These results support the hypothesis
Table 2. Quantification of relevant metabolites and their
variation(a) upon tumor treatment with compounds 1-2 at the
indicated doses administrated per day.
Metabolite Signal Control 1 (10 mg/Kg) 2 (1 mg/Kg) 2 (10 mg/Kg)
Gly 3.55, s 2.17±0.15 2.12±0.32 2.23±0.17 2.00±0.33
Tau 3.42, t 0.43±0.11 0.48±0.06 0.40±0.07 0.74±0.29
S-Inositol 3.33, s - 0.8±1.70 0.12±0.07 1.50±1.70
GPC 3.23, s 0.29±0.05 0.36±0.04 0.38±0.04 0.32±0.10
PC 3.22, s 0.39±0.09 0.43±0.05 0.46±0.05* 0.54±0.05*
Cho 3.20, s 0.49±0.09 0.55±0.10 0.47±0.07 0.83±0.20*
tCho 3.2, m 1.17±0.23 1.60±0.19 1.51±0.16 1.96±0.35
PC/GPC  1.34±0.50 1.19±0.27 1.21±0.26 1.69±0.68
Carn 3.21, s 0.23±0.02 0.26±0.03 0.26±0.03 0.27±0.03
Lac 4.11, q 0.51±0.05 0.70±0.07** 0.63±0.11 0.97±0.34
Ac 1.91, s 0.1±0.02 0.16±0.01 0.20±0.16 0.53±0.40
a Relative intensity to creatine (I/Icreatine). Results represent the mean ± SD of six
experiments. Statistically significant differences of each treatment respect to
control values are indicated as follows: * p ≤ 0.05; ** p ≤ 0.01).
doi: 10.1371/journal.pone.0078391.t002
that the increases in tCho detected by NMR spectroscopy are
associated to the antitumor activity of the compounds.
Taurine levels increased almost two-fold in tumors treated
with the highest dose of thioglycoside with respect to control
values, although the difference was not statistically significant
(0.43±0.11 to 0.74±0.29, Table 2). Taurine concentration has
been correlated with apoptosis in astrocytomas and has been
suggested as an indicator for the clinical monitoring of glioma
apoptosis [42], supporting the hypothesis that the activity of the
thioglycoside could be associated to its ability to induce tumor
apoptosis.
As in the case of cell cultures, treatment with the lowest dose
of compound 2 caused no significant differences in the levels of
Glu, Ala and Val, whereas, Gln levels decreased by 32 % as
compared to non-treated tumors (Figure 5). Gln is a precursor
and storage form of Glu, which slightly increased with
treatments. These changes could be associated with increased
amino acid influx into de TCA cycle (for example of Glu in the
form of α-ketoglutarate), providing an alternative (non
glycolytic) energy source to cancer cells [43], which might be
under stress and/or hypoxia after compound-treatment, and
previous to cell death.
The tumors treated with compounds presented additional
variations in lactate and acetate signals compared to controls
(Figure 5). Although these variations were not statistically
significant, they indicate a trend that deserves discussion.
Acetate concentration appeared to present a dose-response
dependence with thioglycoside 2-treatment. Alterations in
acetate levels have been reported in tumoral tissues, although
the variations depended on the type of tumor. Thus, acetate
levels seemed reduced in lung tumors compared to control
tissue [44], whereas they appeared increased in biopsies of
child neuroblastoma [45]. Lactate also tended to increase after
treatment, particularly with compound 2. Lactate is the end
product of anaerobic glycolysis, normally present in brain tissue
at low concentrations [46]; however, a concentration increase
rapidly follows hypoxia. Both metabolites have been related to
the anaerobic energy metabolism of cancer cells [47,48]. In this
respect, the increased levels of acetate and lactate in the
tumors treated with compound 2 raise the possibility that 2 has
an antiangiogenic effect, leading to a more hypoxic tumor
microenvironment. The promotion of anaerobic metabolism by
thioglycoside 2 is more pronounced in the core of the tumor
than its periphery, as confirmed by the NMR spectra of the
tissue from this region, which showed smaller increases in
acetate and lactate than in the core of the tumor (Table 3).
Along these lines, different studies have reported that hypoxia
can promote apoptosis in tumor cells [49] and plays a crucial
role in regulating the altered lipid metabolism in human
glioblastoma cells [50,51].
Conclusion
Based on the analysis of intact C6 cells and tumor tissues
using 1H HR-MAS NMR spectroscopy, we have established a
good correlation between the changes in metabolic profiles for
in vitro anti-proliferative activity and in vivo antitumor activity
brought about by tumor treatment with glycoside derivatives.
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Specifically, the activity of antitumoral compounds was
associated with an increase in choline and phosphocholine,
observed in both cell culture and tumor tissues. Other
metabolites also change upon tumor treatment in mice, such as
taurine, considered a biomarker of apoptosis. Acetate and
lactate, metabolites that have been related to the anaerobic
energy metabolism of cancer cells, also increase with
increasing antitumoral dose. Thus, these results indicate that
the mode of action of the glycoside involves, at least partially,
alteration of phospholipid metabolism, and results in cell death.
This study is another illustration of the potential of proton NMR
spectroscopy-based metabolomics to help uncover metabolic
processes, as well as to compare in vitro and in vivo models of
human response to pharmacological treatment.
Figure 5.  Histograms summarizing the percentage differences detected in several metabolites between C6 tumor core
tissue treated with glycoside 1 (10 mg/Kg/day) and 2 (1 or 10 mg/Kg/day) and the non-treated control.  Each value in the
histogram represents the mean ± SD of six separate experiments. Positive values indicate the increased presence of a metabolite in
tumors with respect to controls. Asterisks indicate statistically significant differences in a particular metabolite evaluated at p < 0.05.
*, p ≤ 0.05; **, p ≤ 0.01.
doi: 10.1371/journal.pone.0078391.g005
Table 3. Quantification of acetate and lactate and their variation(a) upon tumor treatment with compounds 1-2 at the indicated
doses administrated per day on tissues from the periphery of tumor biopsies.
Metabolite Signal Control 1 (10 mg/Kg) 2 (1 mg/Kg) 2 (10 mg/Kg)
Lac 4.11, q 0.57±0.25 0.59±0.11 0.62±0.12 0.64±0.19
Ac 1.91, s 0.12±0.05 0.15±0.06 0.15±0.07 0.19±0.08
a. Relative intensity to creatine (I/Icreatine). Results represent the mean ± SD of six experiments
doi: 10.1371/journal.pone.0078391.t003
Effect of Drug-Treatment on Cells Using HR-MAS NMR
PLOS ONE | www.plosone.org 9 October 2013 | Volume 8 | Issue 10 | e78391
Acknowledgements
We thank María del Carmen Senin and Juan Antonio Martínez
for their helpful assistance with the statistical analysis.
Author Contributions
Conceived and designed the experiments: IGA LG LRR MNS
AFM RCO. Performed the experiments: IGA LG LRR RCO.
Analyzed the data: IGA LG LRR AFM RCO. Contributed
reagents/materials/analysis tools: IGA LG LRR MNS AFM
RCO. Wrote the manuscript: IGA LG LRR MNS AFM RCO.
References
1. García-Álvarez I, Fernández-Mayoralas A, Garrido L (2011) Effect of
Drugs in Cells and Tissues by NMR spectroscopy. Curr Top Med Chem
11: 27–42. doi:10.2174/156802611793611841. PubMed: 20809892.
2. Lindon JC, Beckonert OP, Holmes E, Nicholson JC (2009) High
resolution magic angle spinning NMR spectroscopy: Application to
biomedical studies. Prog NMR Spectrosc 55: 79–100. doi:10.1016/
j.pnmrs.2008.11.004.
3. Sitter B, Bathen T, Tessem M, Gribbestad I (2009) High resolution
magic angle spinning (HR MAS) MR spectroscopy in metabolic
characterization of human cancer. Prog NMR Spectrosc 54: 239–254.
doi:10.1016/j.pnmrs.2008.10.001.
4. Moestue S, Sitter B, Bathen TF, Tessem MB, Gribbestad IS (2011) HR
MAS MR spectroscopy in Metabolic Characterization of Cancer. Curr
Top Med Chem 11: 2–26. doi:10.2174/156802611793611869. PubMed:
20809888.
5. García-Álvarez I, Corrales G, Doncel-Pérez E, Nieto-Sampedro M,
Fernández-Mayoralas A (2007) Design and Synthesis of Glycoside
Inhibitors of Glioma and Melanoma Growth. J Med Chem 50: 364–373.
doi:10.1021/jm0611556. PubMed: 17228879.
6. Bello C, Dal Bello G, Cea M, Nahimana A, Aubry D et al. (2011) Anti-
cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. Bioorg Med
Chem 19: 7720-7727. doi:10.1016/j.bmc.2011.07.053. PubMed:
22079865.
7. García-Álvarez I, Garrido L, Doncel-Pérez E, Nieto-Sampedro M,
Fernández-Mayoralas A (2009) Detection of Metabolite Changes in C6
Glioma Cells Cultured with Antimitotic Oleyl Glycoside by 1 H MAS
NMR. J Med Chem 52: 1263–1267. doi:10.1021/jm8012807. PubMed:
19199478.
8. García-Álvarez I, Egido-Gabás M, Romero-Ramírez L, Doncel-Pérez E,
Nieto-Sampedro M et al. (2011) Lipid and ganglioside alterations in
tumor cells treated with antimitotic oleyl glycoside. Mol Biosyst 7: 129–
138. doi:10.1039/c0mb00125b. PubMed: 21057675.
9. García-Álvarez I, Groult H, Casas J, Barreda-Manso MA, Yanguas-
Casás N et al. (2011) Synthesis of Antimitotic Thioglycosides: in Vitro
and in Vivo Evaluation of their Anticancer Activity. J Med Chem 54:
6949-6955. doi:10.1021/jm200961q. PubMed: 21866909.
10. Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humpfer E et al. (2010)
Metabolic Profiling of Human Lung Cancer Tissue by 1 H High
Resolution Magic Angle Spinning (HRMAS) NMR Spectroscopy. J
Proteome Res 9: 319-332. doi:10.1021/pr9006574. PubMed:
19908917.
11. Govindaraju V, Young K, Maudsley AA (2000) Proton NMR chemical
shifts and coupling constants for brain metabolites. NMR Biomed 13:
129–153. doi:10.1002/1099-1492(200005)13:3. PubMed: 10861994.
12. Moore DS, McCabe GP (1989) Introduction to the Practice of Statistics.
New York: W.H. Freeman & Co.
13. Brown BW Jr, Hollander M (1977) Statistics: A Biomedical Introduction.
New York: John Wiley & Sons, Inc.
14. Mendenhall W (1989) Introduction to Probability and Statistics. 7th edn.
Boston, Massachusetts: Duxbury Press.
15. Quintero M, Cabañas ME, Arús C (2007) A posible cellular explanation
for the NMR-visible mobile lipid (ML) changes in cultured C6 glioma
cells with growth. Biochim Biophys Acta 1771: 31–44. doi:10.1016/
j.bbalip.2006.10.003. PubMed: 17150408.
16. Griffin JL, Bollard M, Nicholson JK, Bhakoo K (2002) Spectral profiles
of cultured neuronal and glial cells derived from HRMAS 1H NMR
spectroscopy. NMR Biomed 15: 375-384. doi:10.1002/nbm.792.
PubMed: 12357551.
17. Griffin JL, Williams HJ, Sang E, Nicholson JK (2001) Abnormal lipid
profile of dystrophic cardiac tissue as demonstrated by one and two
dimensional magic angle spinning 1H NMR spectroscopy. Magn Reson
Med 46: 249–255. doi:10.1002/mrm.1185. PubMed: 11477627.
18. Gallinger A, Biet T, Pellerin L, Peters T (2011) Insights into Neuronal
Cell Metabolism Using NMR Spectroscopy: Uridyl Diphosphate N-
Acetyl-Glucosamine as a Unique Metabolic Marker. Angew Chem Int
Ed 50: 11672–11674 doi:10.1002/anie.201104836. PubMed:
22012807.
19. Morales A, Lee H, Goñi FM, Kolesnick R, Fernandez-Checa JC (2007)
Sphingolipids and cell death. Apoptosis 12: 923-939. doi:10.1007/
s10495-007-0721-0. PubMed: 17294080.
20. Ohanian J, Ohanian V (2001) Sphingolipids in mammalian cell
signalling. Cell Mol Life Sci 58: 2053–2068. doi:10.1007/PL00000836.
PubMed: 11814056.
21. Gómez-Muñoz A, Kong JY, Salh B, Steinbrecher UP (2004)
Ceramide-1-phosphate blocks apoptosis through inhibition of acid
sphingomyelinase in macrophages. J Lipid Res 45: 99-105. PubMed:
14523050.
22. Hannun YA, Obeid LM (2002) The Ceramide-centric universe of lipid-
mediated cell regulation: stress encounters of the lipid kind. J Biol
Chem 277: 25847–25850. doi:10.1074/jbc.R200008200. PubMed:
12011103.
23. Andrieu-Abadie N, Gouazé V, Salvayre R, Levade T (2001) Ceramide
in apoptosis signaling: relationship with oxidative stress. Free Radic
Biol Med 31: 717–728. doi:10.1016/S0891-5849(01)00655-4. PubMed:
11557309.
24. Brindle KM (2002) Detection of apoptosis in tumors using magnetic
resonance imaging and spectroscopy. Adv Enzyme Regul 42: 101-112.
doi:10.1016/S0065-2571(01)00025-5. PubMed: 12123709.
25. Gallego-Ortega D, Gómez del Pulgar T, Valdés-Mora F, Cebrián A,
Lacal JC (2011) Involvement of human choline kinase alpha and beta
in carcinogenesis: a different role in lipid metabolism and biological
functions. Adv Enzyme Regul 51: 183-194. doi:10.1016/j.advenzreg.
2010.09.010. PubMed: 21035492.
26. Rodríguez-González A, Ramírez de Molina A, Benítez-Rajal J, Lacal
JC (2003) Phospholipase D and choline kinase: their role in cancer
development and their potential as drug targets. Prog Cell Cycle Res 5:
191-201. PubMed: 14593713.
27. Glunde K, Bhujwalla ZM, Ronen SM (2011) Choline metabolism in
malignant transformation. Nat Rev Cancer 11: 835-848. PubMed:
22089420.
28. Aboagye EO, Bhujwalla ZM (1999) Malignant transformation alters
membrane choline phospholipid metabolism of human mammary
epithelial cells. Cancer Res 59: 80-84. PubMed: 9892190.
29. Cao MD, Döpkens M, Krishnamachary B, Vesuna F, Gadiya MM et al.
(2012) Glycerophosphodiester phosphodiesterase domain containing 5
(GDPD5) expression correlates with malignant choline phospholipid
metabolite profiles in human breast cancer. NMR Biomed 25: 1033–
1042. doi:10.1002/nbm.2766. PubMed: 22279038.
30. Farooqui AA, Horrocks LA, Farooqui T (2007) Interactions Between
Neural Membrane Glycerophospholipid and Sphingolipid Mediators: A
Recipe for Neural Cell Survival or Suicide. J Neurosci Res 85: 1834–
1850. doi:10.1002/jnr.21268. PubMed: 17393491.
31. Rodríguez-González A, Ramirez de Molina A, Fernández F, Lacal JC
(2004) Choline kinase inhibition induces the increase in ceramides
resulting in a highly specific and selective cytotoxic antitumoral strategy
as a potential mechanism of action. Oncogene 23: 8247–8259. doi:
10.1038/sj.onc.1208045. PubMed: 15378008.
32. Mirbahai L, Wilson M, Shaw CS, McConville C, Malcomson RDG et al.
(2011) 1H magnetic resonance spectroscopy metabolites as
biomarkers for cell cycle arrest and cell death in rat glioma cells. Int J
Biochem Cell B 43: 990–1001. doi:10.1016/j.biocel.2010.07.002.
33. Lutz NW (2005) From metabolic to metabolomic NMR spectroscopy of
apoptotic cells. Metabolomics 1: 251–268. doi:10.1007/
s11306-005-0005-z.
Effect of Drug-Treatment on Cells Using HR-MAS NMR
PLOS ONE | www.plosone.org 10 October 2013 | Volume 8 | Issue 10 | e78391
34. Podo F (1999) Tumour phospholipid metabolism. NMR Biomed 12:
413–439. doi:10.1002/(SICI)1099-1492(199911)12:7. PubMed:
10654290.
35. Morse DL, Raghunand N, Sadarangani P, Murthi S, Job C et al. (2007)
Response of choline metabolites to docetaxel therapy is quantified in
vivo by localized 31P MRS of human breast cancer xenografts and in
vitro by high-resolution 31P NMR spectroscopy of cell extracts. Magn
Reson Med 58: 270–280. doi:10.1002/mrm.21333. PubMed: 17654590.
36. Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP et al. (2005)
Increases in NMR-visible lipid and glycerophosphocholine during
phenylbutyrate induced apoptosis in human prostate cancer cells.
Biochim Biophys Acta 1734: 1–12. doi:10.1016/j.bbalip.2005.01.008.
PubMed: 15866478.
37. Yoshii Y, Furukawa T, Yoshii H, Mori T, Kiyono Y et al. (2009) Cytosolic
acetyl-CoA synthetase affected tumor cell survival under hypoxia: the
possible function in tumor acetyl-CoA/acetate metabolism. Cancer Sci
100: 821-827. doi:10.1111/j.1349-7006.2009.01099.x. PubMed:
19445015.
38. Kinoshita Y, Yokota A (1997) Absolute Concentrations of Metabolites in
Human Brain Tumors Using In Vitro Proton Magnetic Resonance
Spectroscopy. NMR Biomed 10: 2–12. doi:10.1002/
(SICI)1099-1492(199701)10:1. PubMed: 9251109.
39. Michaelis T, Helms G, Merboldt KD, Hänicke W, Bruhn H et al. (1993)
Identification of Scyllo-inositol in proton NMR spectra of human brain in
vivo. NMR Biomed 6: 105-109. doi:10.1002/nbm.1940060116.
PubMed: 8384468.
40. Kaiser LG, Schuff N, Cashdollar N, Weiner MW (2005) Scyllo-inositol in
normal aging human brain: 1 H magnetic resonance spectroscopy
study at 4 Tesla. NMR Biomed 18: 51–55. doi:10.1002/nbm.927.
PubMed: 15468140.
41. Venugopal N, McCurdy B, Al Mehairi S, Alamri A, Sandhu GS et al.
(2012) Short echo time in vivo prostate 1H-MRSI. Magn Reson Imaging
30: 195–204. doi:10.1016/j.mri.2011.09.020. PubMed: 22154684.
42. Opstad KS, Bell BA, Griffiths JR, Howe FA (2009) Taurine: a potential
marker of apoptosis in gliomas. Br J Cancer 100: 789–794. doi:
10.1038/sj.bjc.6604933. PubMed: 19223899.
43. Somashekar BS, Kamarajan P, Danciu T, Kapila YL, Chinnaiyan AM et
al. (2011) Magic Angle Spinning NMR-Based Metabolic Profiling of
Head and Neck Squamous Cell Carcinoma Tissues. J Proteome Res
10: 5232-5241. doi:10.1021/pr200800w. PubMed: 21961579.
44. Duarte IF, Rocha CM, Barros AS, Gil AM, Goodfellow BJ et al. (2010)
Can nuclear magnetic resonance (NMR) spectroscopy reveal different
metabolic signatures for lung tumours? Virchows Arch 457: 715–725.
doi:10.1007/s00428-010-0993-6. PubMed: 20941505.
45. Imperiale A, Elbayed K, Moussallieh FM, Neuville A, Piotto M et al.
(2011) Metabolomic Pattern of Childhood Neuroblastoma Obtained by
1 H-High-Resolution Magic Angle Spinning (HRMAS) NMR
Spectroscopy. Pediatr Blood Cancer 56: 24–34. doi:10.1002/pbc.
22668. PubMed: 20949594.
46. Veech RL (1991) The metabolism of lactate. NMR Biomed 4: 53–58.
doi:10.1002/nbm.1940040204. PubMed: 1859786.
47. Mazzio EA, Smith B, Soliman KFA (2010) Evaluation of endogenous
acidic metabolic products associated with carbohydrate metabolism in
tumor cells. Cell Biol Toxicol 26: 177–188. doi:10.1007/
s10565-009-9138-6. PubMed: 19784859.
48. Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat
Rev Cancer 11: 393-410. doi:10.1038/nrc3064. PubMed: 21606941.
49. Kunz M, Ibrahim SM (2003) Molecular responses to hypoxia in tumor
cells. Mol Cancer 2: 1-13. doi:10.1186/1476-4598-2-1. PubMed:
12537587.
50. Laurenti G, Benedetti E, D’Angelo B, Cristiano L, Cinque B et al. (2011)
Hypoxia Induces Peroxisome Proliferator-Activated Receptor a
(PPARa) and Lipid Metabolism Peroxisomal Enzymes in Human
Glioblastoma Cells. J Cell Biochem 112: 3891–3901. doi:10.1002/jcb.
23323. PubMed: 21866563.
51. Benedetti E, Galzio R, Laurenti G, D'Angelo B, Melchiorre E et al.
(2010) Lipid metabolism impairment in human gliomas: expression of
peroxisomal proteins in human gliomas at different grades of
malignancy. Int J Immunopathol Pharmacol 23: 235-246. PubMed:
20378009.
Effect of Drug-Treatment on Cells Using HR-MAS NMR
PLOS ONE | www.plosone.org 11 October 2013 | Volume 8 | Issue 10 | e78391
